Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.

Yang JC, Han B, De La Mora Jiménez E, Lee JS, Koralewski P, Karadurmus N, Sugawara S, Livi L, Basappa NS, Quantin X, Dudnik J, Ortiz DM, Mekhail T, Okpara CE, Dutcus C, Zimmer Z, Samkari A, Bhagwati N, Csőszi T

Open source

DOI: 10.1016/j.jtho.2023.12.023
Published: 2024 Jun
Container: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2023.12.023,
  title = {Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1\% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.},
  author = {Yang JC and Han B and De La Mora Jiménez E and Lee JS and Koralewski P and Karadurmus N and Sugawara S and Livi L and Basappa NS and Quantin X and Dudnik J and Ortiz DM and Mekhail T and Okpara CE and Dutcus C and Zimmer Z and Samkari A and Bhagwati N and Csőszi T},
  year = {2024},
  journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  doi = {10.1016/j.jtho.2023.12.023},
  url = {https://doi.org/10.1016/j.jtho.2023.12.023}
}

RIS

TY  - JOUR
TI  - Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
AU  - Yang JC
AU  - Han B
AU  - De La Mora Jiménez E
AU  - Lee JS
AU  - Koralewski P
AU  - Karadurmus N
AU  - Sugawara S
AU  - Livi L
AU  - Basappa NS
AU  - Quantin X
AU  - Dudnik J
AU  - Ortiz DM
AU  - Mekhail T
AU  - Okpara CE
AU  - Dutcus C
AU  - Zimmer Z
AU  - Samkari A
AU  - Bhagwati N
AU  - Csőszi T
PY  - 2024
JO  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
DO  - 10.1016/j.jtho.2023.12.023
UR  - https://doi.org/10.1016/j.jtho.2023.12.023
ER  -

APA

JC, Y., B, H., E, D. L. M. J., JS, L., P, K., N, K., S, S., L, L., NS, B., X, Q., J, D., DM, O., T, M., CE, O., C, D., Z, Z., A, S., N, B., & T, C. (2024). Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2023.12.023

Source records

pubmed · retrieved 2026-09-26T08:34:08.006Z